Johnson & Johnson: J&J Declares 'Sustained Disease Control' With Bladder Cancer Drug-Device Combo
The targeted drug release device TAR-200 shows promising response and disease-free survival rates in specific populations of patients with non-muscle-invasive bladder cancer.
Read full article »
Johnson & Johnson is a New Jersey-based firm that engages in research, manufacturing and sale of healthcare products including consumer, pharmaceutical and medical devices.
Read more